Smarter Drug Discovery Yields Promising Results in Multiple Myeloma Therapy

Using an innovative screening assay and an enlightened approach to drug discovery, a Cleveland Clinic-led team of researchers has identified CCF642 — a small-molecule compound that represents a new class of anticancer agents. CCF642 has broad anti-myeloma activity in vivo, prolonging survival in a mouse model of multiple myeloma comparable to the survival extension achieved by the FDA-approved first-line therapeutic agent bortezomib.